Expertise in
19
conditions

Dr. Ronald Fogel

Gastroenterology
GI Medicine Associates PC
30795 23 Mile Rd Ste 206, 
Chesterfield, MI 
Expertise in
19
conditions
GI Medicine Associates PC
30795 23 Mile Rd Ste 206, 
Chesterfield, MI 

Overview

Ronald Fogel is a Gastroenterologist practicing medicine in Chesterfield, Michigan.

Dr. Fogel is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Hemorrhagic Proctocolitis, Acute Pancreatitis, Hereditary Pancreatitis, Endoscopy, and Colonoscopy.

He is actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 22 clinical trials.

Specialties

Gastroenterology

Licenses

Internal Medicine in MI

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

GI Medicine Associates PC
30795 23 Mile Rd Ste 206, Chesterfield, MI 48047

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
3-Arm Randomized Placebo Controlled Double Blind Phase 3 Study to Evaluate Safety and Efficacy of Once-Daily and Twice-Daily Hydrocortisone Acetate 90 mg Suppository Administered With a Sephure Applicator in Subjects With Ulcerative Colitis
3-Arm Randomized Placebo Controlled Double Blind Phase 3 Study to Evaluate Safety and Efficacy of Once-Daily and Twice-Daily Hydrocortisone Acetate 90 mg Suppository Administered With a Sephure Applicator in Subjects With Ulcerative Colitis
Enrollment Status: Completed
Publish Date: July 30, 2025
Intervention Type: Combination product
Study Drug: Hydrocortisone acetate suppository administered with Sephure applicator
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Study to Evaluate the Efficacy and Long-term Safety of SHR0302 Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 3 Study to Evaluate the Efficacy and Long-term Safety of SHR0302 Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Enrollment Status: Unknown
Publish Date: September 05, 2023
Intervention Type: Drug
Study Drug: SHR0302
Study Phase: Phase 3
View 9 Less Clinical Trials

12 Total Publications

Plecanatide Improves Symptoms of Irritable Bowel Syndrome with Constipation: Results of an Integrated Efficacy and Safety Analysis of Two Phase 3 Trials.
Plecanatide Improves Symptoms of Irritable Bowel Syndrome with Constipation: Results of an Integrated Efficacy and Safety Analysis of Two Phase 3 Trials.
Journal: International journal of general medicine
Published: March 21, 2023
Similar Doctors
Expertise in
24
conditions
Dr. Stuart Gordon
Gastroenterology
Expertise in
24
conditions
Dr. Stuart Gordon
Gastroenterology
Referral may be required

Henry Ford Hospital

2799 W Grand Blvd, 
Detroit, MI 
 (25.7 miles away)
313-916-2600
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stuart Gordon is a Gastroenterologist practicing medicine in Detroit, Michigan. Dr. Gordon is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Hepatitis, Hepatitis C, Primary Biliary Cholangitis, Endoscopy, and Liver Transplant.

Expertise in
95
conditions
Dr. Mohammed Barawi
Gastroenterology
Expertise in
95
conditions
Dr. Mohammed Barawi
Gastroenterology
Referral may be required

Henry Ford Medical Center-New Baltimore

36750 26 Mile Rd, 
Chesterfield, MI 
 (1.6 miles away)
586-879-2000
Languages Spoken:
English
See accepted insurances

Mohammed Barawi is a Gastroenterologist practicing medicine in Chesterfield, Michigan. Dr. Barawi is highly rated in 95 conditions, according to our data. His clinical expertise encompasses Hereditary Pancreatitis, Pancreatic Pseudocyst, Gastrointestinal Bleeding, Endoscopy, and Colonoscopy.

Expertise in
25
conditions
Dr. William D. Chey
Gastroenterology | Internal Medicine
Expertise in
25
conditions
Dr. William D. Chey
Gastroenterology | Internal Medicine
Referral may be required

Taubman Center

1500 E Medical Center Dr, Floor 3 Reception D, 
Ann Arbor, MI 
 (54.3 miles away)
888-229-7408
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Chey received his BA degree from the University of Pennsylvania and medical degree & training in internal medicine at the Emory University School of Medicine. He went on to complete a fellowship in gastroenterology at the University of Michigan. Since completing this fellowship, Dr. Chey has remained at the University of Michigan, where he is H. Marvin Pollard Professor of Gastroenterology, Professor of Nutrition Sciences, and Chief, Division of Gastroenterology & Hepatology. Dr. Chey runs a very active clinical research group which has received funding from federal and private sources. Dr. Chey has authored more than 400 manuscripts, reviews and book chapters yielding an H-index of 50. He is former Co-editor-in-Chief of the American Journal of Gastroenterology (2010-2016) and serves on the editorial boards of several other journals. He serves as a member of the Board of Trustees and in 2026, will become President of the American College of Gastroenterology. He is a member of the Board of Directors of the Rome Foundation and IFFGD. He has participated in and directed numerous national and international continuing medical education programs in gastroenterology, and has been elected to the roster of Best Doctors since 2001 and America's™ Top Doctors since 2009. Dr. Chey has received numerous awards including the Berk-Fise Award for outstanding clinical service from the ACG, the Distinguished Clinician Award from the AGA, Dean’s Outstanding Clinician Award, Dean’s Award for Innovation and Commercialization, and the Healio Disruptive Innovator Award. Dr. Chey is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Irritable Bowel Syndrome (IBS), Diarrhea, Chronic Idiopathic Constipation (CIC), Endoscopy, and Colonoscopy. Dr. Chey is board certified in Internal Medicine and Gastroenterology.

Frequently Asked Questions about Dr. Ronald Fogel

How do I make an appointment with Dr. Ronald Fogel?

You can book an appointment with Dr. Ronald Fogel by calling their office at 586-598-5131. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ronald Fogel a top-rated expert for Hemorrhagic Proctocolitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ronald Fogel is classified as an Distinguished expert for Hemorrhagic Proctocolitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ronald Fogel specialize in?

While Dr. Ronald Fogel is a Gastroenterology, they have specific expertise in Hemorrhagic Proctocolitis, Acute Pancreatitis, and Hereditary Pancreatitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Ronald Fogel participate in research or clinical trials?

Yes. Dr. Ronald Fogel has published 12 articles and abstracts on conditions like Hemorrhagic Proctocolitis. You can view a list of Dr. Ronald Fogel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ronald Fogel accept my insurance?

Dr. Ronald Fogel accepts most major insurance plans, including Humana and Meridian Choice. We recommend calling the office directly at 586-598-5131 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fogel's expertise for a condition
ConditionClose
    View All 15 Advanced Conditions
    View All 40 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile